Last updated: February 23, 2026
What Is the Scope of EP3978074?
EP3978074, titled "Methods and compositions for treating disease via modulation of amino acid levels," covers methods involving altering amino acid levels for therapeutic purposes. The patent extends protection primarily over a class of compounds, administration methods, and treatment indications linked to amino acid modulation.
Key points:
- Focuses on pharmaceutical compositions that regulate amino acid levels.
- Claims methods for treating diseases where amino acid imbalance is involved.
- Includes specific formulations, dosing regimens, and targeted patient populations.
- Encompasses both diagnostic and therapeutic applications.
The patent's scope broadly covers techniques and compositions used for therapeutic amino acid manipulation, covering treatments for diseases such as cancer, metabolic disorders, and neurodegenerative conditions.
How Are the Claims Structured?
EP3978074 contains 25 claims, categorized into independent and dependent claims.
Independent Claims
- Claim 1: A method of treating a disease associated with amino acid imbalance, comprising administering a composition that modulates levels of at least one amino acid.
- Claim 2: A pharmaceutical composition comprising a compound that influences amino acid levels.
- Claim 9: A diagnostic method to identify subjects suitable for treatment based on amino acid levels.
Dependent Claims
- Specify particular amino acids (e.g., glutamine, arginine).
- Detail dosage forms such as oral tablets, injectables.
- Define dosing schedules and patient eligibility criteria.
- Cover specific disease states (e.g., certain cancers, metabolic syndromes).
The claims target both therapeutic and diagnostic applications, with a primary emphasis on modulation of amino acids to treat or diagnose diseases.
Patent Landscape Analysis
Key Patent Families and Related Patents
- Prior art focus: Includes patents on amino acid manipulation, metabolic pathway intervention, and enzyme inhibitors affecting amino acid metabolism.
- Major applicants: The patent's applicant is Innovative Biotech Ltd., with related filings in jurisdictions including US, Japan, and China.
- Related patents: Several patents exist on amino acid transport modulators, enzyme inhibitors, and metabolic modifiers.
Trends and Clusters
- Increasing filings for amino acid-targeted therapies over the past five years.
- Growth in diagnostics related to amino acid profiling.
- Focus on personalized medicine using amino acid signatures.
Patent Strengths and Weaknesses
Strengths:
- Broad claims covering multiple diseases and treatment modalities.
- Inclusion of diagnostic methods enhances commercial potential.
- Multiple claim dependencies allow for fallback positions.
Weaknesses:
- Some claims may be challenged for lacking novelty if prior art exists.
- The specificity of compounds could be narrow, risking design-around attempts.
- Potential for overlapping claims with existing patents in amino acid transporter inhibitors.
Patent Validity and Freedom to Operate
- Based on the current patent landscape, there are no active litigations concerning EP3978074.
- However, several patents on related methods and compositions could pose infringement risks.
- Validity may depend on prior art close to claim scope, especially regarding specific amino acids and disease targets.
Conclusions on Patent Position
- EP3978074 has a strong position, with broad claims covering therapeutic and diagnostic methods.
- It fills a niche related to amino acid modulation but faces competition from existing metabolic pathway patents.
- The patent's strength relies on the novelty of specific compounds and treatment methods.
Key Takeaways
- The patent claims methods and compositions aimed at amino acid modulation with broad disease applicability.
- The claim structure balances method claims and composition claims, including diagnostic applications.
- The patent landscape shows increasing activity in amino acid-based therapies, indicating a competitive environment.
- Validity and freedom to operate depend on close prior art analysis, especially regarding specific amino acids and disease contexts.
FAQs
1. Does EP3978074 cover all amino acids or specific ones?
It broadly covers at least one amino acid, with specific claims focusing on glutamine and arginine, among others.
2. What diseases are targeted by this patent?
Claims focus on diseases linked to amino acid imbalances, including cancers, metabolic disorders, and neurodegenerative diseases.
3. Are the diagnostic claims enforceable?
Yes, they cover methods for identifying suitable candidates based on amino acid levels, which can have commercial applications.
4. How does this patent compare to existing amino acid therapy patents?
It claims broad methods and compositions but may face challenges if prior art covers similar therapeutic strategies.
5. What should licensors or licensees consider regarding freedom to operate?
They should assess overlapping claims, particularly in amino acid transport and enzyme modulators, to avoid infringement.
References
[1] European Patent Office. (2022). EP3978074 patent publication.
[2] WIPO. (2021). International Patent Classification for amino acid treatment inventions.
[3] PatentScope. (2022). Patent landscape analysis on amino acid modulation patents.
